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A Case of von Hippel–Lindau Disease with Colorectal 
Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas
Case Report
von Hippel–Lindau (VHL) disease is an autosomal dominant inherited tumor syn-
drome associated with mutations of the VHL tumor suppressor gene located on chro-
mosome 3p25. The loss of functional VHL protein contributes to tumorigenesis. This
condition is characterized by development of benign and malignant tumors in the
central nervous system (CNS) and the internal organs, including kidney, adrenal
gland, and pancreas. We herein describe the case of a 74-year-old man carrying the
VHL gene mutation who was affected by simultaneous colorectal adenocarcinoma,
renal clear cell carcinoma, and hemangioblastomas of CNS.
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Introduction
von Hippel–Lindau (VHL) disease is an autosomal domi-
nant inherited tumor syndrome associated with mutations
of the VHL tumor suppressor gene located on chromosome
3p25 [1,2]. The loss of functional VHL protein contributes to
tumorigenesis [3]. This condition is characterized by devel-
opment of benign and malignant tumors in the central nerv-
ous system (CNS) and the internal organs, including kidney,
adrenal gland, and pancreas [1]. We herein describe the case
of a 74-year-old man carrying the VHL gene mutation who
was affected by simultaneous colorectal adenocarcinoma,
renal clear cell carcinoma, and hemangioblastomas in CNS.
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Case Report
In January 2013, a 74-year-old man was admitted to the 
Department of Neurosurgery at Yonsei University College
of Medicine due to gait disturbance and tingling sensation
of both legs. The patient was receiving beta-adrenergic 
antagonist and calcium channel blocker for arterial hyper-
tension. He had lost his vision in the left eye due to cataract
and amblyopia in the right eye due to retinitis which had 
occurred 30 years ago. The patient’s family history included
a mother with a brain tumor of unconfirmed pathology, and
both brothers with renal cell carcinoma with VHL gene 
mutation (Fig. 1). Serum carcinoembryonic antigen (CEA)
was elevated to 11.78 ng/mL (normal value, 0.0 to 5.0
ng/mL). Although he had no history of diabetes mellitus,
serum glucose level was 462 mg/dL and HbA1c was 11.7%,
which led to a new diagnosis of diabetes mellitus, and initi-
ation of insulin therapy. Whole spine magnetic resonance 
imaging (MRI) showed multiple enhancing nodular lesions
of the spinal canal suspected leptomeningeal metastasis of
unknown primary malignancy (Fig. 2A). Positron emission
tomography whole body scan showed intense fludeoxyglu-
cose uptake in a 3-cm-sized heterogeneous mass in the right
kidney and focal mural thickening in the sigmoid colon 
(Fig. 2B and C). Colonoscopy showed a 5-cm-sized ulceroin-
filtrative lesion in the sigmoid colon and a polypoid lesion
in the rectum. Subsequent histological examination con-
firmed the diagnosis of adenocarcinoma and high grade 
tubular adenoma with focal carcinoma in situ transformation,
respectively. Incisional biopsy of the spinal mass was per-
formed and the histological examination revealed heman-
gioblastoma.
The patient underwent laparoscopic right partial nephrec-
tomy, laparoscopic anterior resection of the sigmoid colon,
and transanal endoscopic operation of the rectum. Histologic
examination of the kidney revealed renal clear cell carcinoma
(size, 1.9!1.7 cm), Fuhrman nuclear grade 3 (pT1aN0M0;
stage I). In the sigmoid colon, gross pathology showed an 
ulcerofungating tumor (size, 4.2!3.6 cm) and 3 of 23 exam-
ined regional lymph nodes were metastasis. Subsequent 
histological examination confirmed typical features of colon
adenocarcinoma (pT3N1bM0; stage IIIB). The rectum speci-
men was confirmed to be a 0.5-cm-sized well differentiated
adenocarcinoma (pT1N0M0; stage I). The postoperative CEA
level was 4.24 ng/mL. 
Regarding clinical decision processes, we initially sus-
pected VHL disease. Subsequently, polymerase chain reac-
tion (PCR) sequencing analysis of VHL gene showed
p.Glu70Lys (c.208G > A) mutation in exon 1, confirming 
the diagnosis of VHL disease (Fig. 3). Result of endocrine
hormonal evaluation for pheochromocytoma was within
normal range.
His two sons were screened for VHL disease using PCR
sequencing analysis, and one progenity showed p.Glu70Lys
(c.208G > A) mutation in exon 1, identical to his father. He
underwent ophthalmic examination, abdomen-pelvic com-
puted tomography scan and blood test for catecholamine
metabolites, but there were no abnormal findings. 
After 3 weeks from discharge, he was admitted to hospital
complaining of worsened gait disturbance and numbness 
of both soles. Brain MRI showed three enhancing lesions in
bilateral cerebellar hemispheres and left cerebellar tonsil,
suggesting hemangioblastomas (Fig. 4). The patient under-
went gamma knife surgery in cerebellar lesions and pallia-
tive radiotherapy to T9-S1 spine with a total of 45 Gy in 25
daily fractions. 
After one month, follow-up imaging studies showed stable
lesions in the brain and spine, but there was a newly devel-
oped hepatic metastasis in S6 and an enlarged aortocaval
lymph node (Fig. 5). Concurrent serum CEA level increased
to 19.54 ng/mL. The multidisciplinary team decided to per-
form surgery, laparoscopic wedge resection of liver and 
excision of aortocaval lymph node. Histologic examination
of liver revealed a 1.6!1.2-cm-sized metastatic adenocarci-
noma, moderately differentiated, clinically from colon.
Pathologic finding indicated that the aortocaval lymph node
was metastatic carcinoma, favoring renal clear cell carci-
noma. He is on regular follow-up in the outpatient clinic and
imaging studies show no evidence of recurrence and CEA
level is stabilized within normal range.
Patients with mutation (VHL) and clinical disease (arrow: case patient) 
Subjects with mutation without clinical disease
Healthy subjects
Brain tumor
75 yr 70 yr
RCC
46 yr 44 yr 40 yr
Brain
hemorrhage
Hematologic
malignancy
79 yr
RCC
Pancreatic
cancer
Fig. 1.  Pedigree presenting VHL gene mutation status and
malignancy. Both brothers were diagnosed with renal cell
carcinoma (RCC) with VHL gene mutation and one of his
sons was confirmed VHL mutation without clinical mani-
festation. 
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Fig. 2. (A) Spine magnetic resonance imaging showed multiple enhancing nodular lesions of the spinal canal suspected lep-
tomeningeal metastasis of unknown primary malignancy. Positron emission tomography computed tomography whole
body scan showed a 3-cm enhancing heterogenous mass in the right kidney (arrow) (B), focal mural thickening with intense
fludeoxyglucose uptake in the sigmoid colon (C).
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Fig. 3.  Polymerase chain reaction sequencing analysis of von Hippel–Lindau (VHL) gene showed a p.Glu70Lys (c.208G > A)
mutation in exon 1, confirming the diagnosis of VHL disease.
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Discussion
VHL disease is a familial multisystem syndrome associ-
ated with germline mutation of the VHL tumor suppressor
gene at chromosome 3p25. It occurs in approximately 1 in
36,000 live births [2]. The diagnosis of VHL can be made clin-
ically if a single VHL-associated tumor (that is a heman-
gioblastoma, pheochromocytoma, or renal clear cell carc-
inoma) occurs in an individual with a family history of VHL.
The diagnosis can also be made clinically in the absence of a
family history if a second VHL associated tumor occurs in an
individual with hemangioblastoma (that is two or more 
hemangioblastomas or both a hemangioblastoma and 
a pheochromocytoma or clear cell renal carcinoma). As 
approximately 20% of VHL disease results from de novo
mutations, the absence of a family history in no way excludes
the diagnosis [4]. The most common lesions are CNS (retinal
and cerebellar hemangioblastoma), kidney (renal clear cell
cell carcinoma and renal cyst), adrenal gland/paraganglia
(pheochromocytoma/paraganglioma), pancreas (neuroen-
docrine tumors, pancreatic cyst, or serous cystadenoma), and
middle ear (endolymphatic sac tumor) [5].
In this case report, we observed the coexistence of three
primary tumors at diagnosis: renal clear cell carcinoma and
CNS hemangioblastomas, which are known to present in
VHL disease, and colorectal adenocarcinomas. Because his
eyes were damaged too severely to evaluate for retina con-
dition, we presumed that he might have had retinal heman-
gioblastoma in the past. To date, only one case of colorectal
carcinoma in a patient with VHL syndrome has been desc-
ribed [6]. 
The mechanism of VHL syndrome in tumorigenesis is 
hypoxia inducible factors (HIF1 and HIF2). Either hypoxia
or absent or inactive VHL protein results in stabilization of
HIF1 and HIF2, which then acts as a transcription factor 
Fig. 4.  Brain magnetic resonance imaging showed three enhancing lesions (arrows) in bilateral cerebellar hemispheres (A,
B) and left cerebellar tonsil (C), suggesting hemangioblastomas.
A B C
Fig. 5.  Abdomen-pelvic computed tomography scan showed newly developed hepatic metastasis in S6 (A) and an enlarged
aortocaval lymph node (arrow) (B).
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initiating cellular cascade for hypoxic response. This hypoxic
response affects glucose uptake and metabolism, angiogen-
esis, extracellular matrix formation, chemotaxis and cell 
proliferation, and then activates downstream targets, includ-
ing vascular endothelial growth factor (VEGF), platelet 
derived growth factor (PDGF), and transforming growth 
factor ! [7]. 
Several studies offer evidence suggesting that down regu-
lation of VHL provides a proangiogenic impulse for devel-
opment of colorectal cancer. Xue et al. [8] suggested that
chronic increases in expression of HIF in colon initiate 
protumorigenic signaling. In addition, in the progression
from colorectal adenoma to carcinoma, VEGF plays an 
important role in formation of new capillaries to increase
oxygen and nutrient demands [9]. 
Nevertheless, in this case report, we have weight to explain
that synchronous colon and rectal adenocarcinomas devel-
oped sporadically in a patient with VHL disease. In Korea,
colon cancer is the third most common cancer overall, and
the second most common cancer in men [10]. In the general
population, the coexistence of primary malignancies of colon
and other organs is difficult to assess because the etiology 
is complex, including both genetic and environmental risk
factors.
Early detection and proper intervention currently offer the
best hope for minimizing the burden of VHL disease in order
to prevent avoidable morbidity and mortality. Either surgical
resection or radiation therapy has a role in management of
hemangioblastoma in CNS. However, no randomized clini-
cal trials comparing these approaches, or are any random-
ized trials addressing the optimal timing of therapeutic
intervention have been reported. The principle advantage 
of radiation therapy is that it is noninvasive and does not
carry the risks of conventional surgery, such as difficulty to
approach, infection, anesthetic complication, stroke, or 
neurologic deficits in CNS. In particular, in patients with
VHL disease, multiple hemangioblastomas tend to develop
over time within both the brain and spine, often necessitating
multiple operations over a patient's lifetime. Even though
these operations take successfully, the patients show gradual
disability. In such cases, radiation therapy may be a much
safer option [11]. In our case, the patient underwent multiple
steps of surgery and radiotherapy. In particular, heman-
gioblastomas in CNS are controlled safely under radiation
therapy regardless of symptoms.
There is no effective therapeutic agent in VHL disease. 
A small number of clinical trials were conducted, and further
study will be needed. For example, Kim et al. [12] reported
on sunitinib, tyrosine kinase inhibitor, which inhibits the
VEGF and PDGF receptors, and is administered in patients
who had metastatic renal cell carcinoma with complicating
VHL disease, and it prolonged the duration of response time.
As early detection and intervention in time is important for
VHL patients, routine surveillance and a multidisciplinary
appr-oach due to multisystem involvement are needed.
Thus, all VHL patients and relatives who are at risk should
be entered into comprehensive screening programs at special
referral centers (for example see Table 1 [13]).
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Table 1. Example of a routine surveillance protocol for von Hippel–Lindau disease
Protocol
Screen for retinal angioma
Annual ophthalmic examinations (direct and indirect ophthalmoscopy), beginning in infancy or early childhood
Screen for CNS hemangioblastoma
MRI scans of the head for every 12-36 months, beginning in adolescence
Screen for renal cell carcinoma and pancreatic tumors
MRI (or ultrasound) examinations of the abdomen every 12 months, beginning from the age of 16 years
Screen for pheochromocytoma
Annual blood pressure monitoring and 24-hour urine studies for catecholamine metabolites
More intense surveillance (e.g., annual measurement of plasma normetanephrine levels, adrenal imaging, beginning from 
the age of 8 years should be considered in families at high-risk for pheochromocytoma)
Adopted from Maher’s paper [13], Curr Mol Med. 2004;4:833-42, with permission of Bentham Science Publishers. CNS, central
nervous system; MRI, magnetic resonance imaging. 
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